TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation

Oncogene

Volumn 36, Issue 11, 2017, Pages 1585-1596

  Kang, J ^a   Kim, W ^a   Lee, S ^a   Kwon, D ^a   Chun, J ^a   Son, B ^a   Kim, E ^a   Lee, J M ^a   Youn, H ^b   Youn, B ^a  

^a Pusan National University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; MICRORNA; MICRORNA 183; MICRORNA 33A; TRANSCRIPTION FACTOR ACTIVATING ENHANCER BINDING PROTEIN 2C; UNCLASSIFIED DRUG; AKAP12 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; MIRN183 MICRORNA, HUMAN; MIRN33 MICRORNA, HUMAN; TFAP2C PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CARCINOGENESIS; CELL CYCLE; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

A KINASE ANCHOR PROTEINS; ANIMALS; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-2;

EID: 84991035938     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.328     Document Type: Article

References (56)

1. Shai A, Dankort D, Juan J, Green S, McMahon M. TP53 silencing bypasses growth arrest of BRAFV600E-induced lung tumor cells in a two-switch model of lung tumorigenesis. Cancer Res 2015; 75: 3167-3180.
2. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010; 8: 740-801.
3. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010; 7: 401-414.
4. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 2014; 124: 1582-1586.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
7. Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutationspecific selectivity in non-small cell lung cancer. Acta Pharmacol Sin 2015; 36: 291-297.
8. Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C. [Targeting the RAS signalling pathway in cancer]. Bull Cancer 2011; 98: 1019-1028.
9. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011; 3: 1787-1808.
10. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005; 6: 246.
11. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000; 260: 1-12.
12. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 2004; 64: 8256-8261.
13. Ailan H, Xiangwen X, Daolong R, Lu G, Xiaofeng D, Xi Q et al. Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells. BMC Cancer 2009; 9: 279.
14. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010; 49: 948-962.
15. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996; 35: 262-264.
16. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6: 60.
17. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
18. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
19. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
20. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics 2013; 6: 53.
21. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
22. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100-111.
23. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010; 5: e10312.
24. Leung WK, He M, Chan AW, Law PT, Wong N. Wnt/beta-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett 2015; 362: 97-105.
25. Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol 2015; 36: 8121-8126.
26. Zhou J, Xu D, Xie H, Tang J, Liu R, Li J et al. miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1alpha. Cancer Biol Ther 2015; 16: 846-855.
27. Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramirez CM, Chamorro-Jorganes A et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012; 11: 922-933.
28. Yoon DK, Jeong CH, Jun HO, Chun KH, Cha JH, Seo JH et al. AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett 2007; 254: 111-118.
29. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9: 13-22.
30. Grossel MJ, Hinds PW. From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle 2006; 5: 266-270.
31. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-572.
32. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, Li H et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol 2013; 94: 73-78.
33. Kim E, Youn H, Kwon T, Son B, Kang J, Yang HJ et al. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells. Cancer Res 2014; 74: 5520-5531.
34. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-824.
35. Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003; 9: 4695-4704.
36. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784-13789.
37. Bamforth SD, Braganca J, Eloranta JJ, Murdoch JN, Marques FI, Kranc KR et al. Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet 2001; 29: 469-474.
38. Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC et al. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 2002; 277: 8559-8565.
39. Liu H, Tan BC, Tseng KH, Chuang CP, Yeh CW, Chen KD et al. Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation. EMBO Rep 2007; 8: 394-400.
40. Wong PP, Miranda F, Chan KV, Berlato C, Hurst HC, Scibetta AG. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol 2012; 32: 1633-1644.
41. Williams CM, Scibetta AG, Friedrich JK, Canosa M, Berlato C, Moss CH et al. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J 2009; 28: 3591-3601.
42. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH. Loss of the SSeCKS/ Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res 2008; 68: 5096-5103.
43. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T et al. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol 2009; 217: 32-41.
44. Perkins SM, Bales C, Vladislav T, Althouse S, Miller KD, Sandusky G et al. TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Res Treat 2015; 152: 519-531.
45. Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene 2015; 34: 436-444.
46. Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM et al. Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell 2014; 25: 748-761.
47. Odegaard E, Staff AC, Kaern J, Florenes VA, Kopolovic J, Trope CG et al. The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol 2006; 100: 462-468.
48. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res 2006; 66: 5599-5607.
49. Su B, Bu Y, Engelberg D, Gelman IH. SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C-Raf/MEK/ERK pathway. J Biol Chem 2010; 285: 4578-4586.
50. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
51. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 2013; 7: 112-120.
52. Yang HJ, Youn H, Seong KM, Jin YW, Kim J, Youn B. Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. J Biol Chem 2013; 288: 2965-2975.
53. Kim W, Youn H, Seong KM, Yang HJ, Yun YJ, Kwon T et al. PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat Res 2011; 176: 539-552.
54. Kim W, Kim E, Yang HJ, Kwon T, Han S, Lee S et al. Inhibition of hedgehog signalling attenuates UVB-induced skin photoageing. Exp Dermatol 2015; 24: 611-617.
55. Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, Kim YH et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol 2011; 82: 524-534.
56. Kwon T, Youn H, Son B, Kim D, Seong KM, Park S et al. DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer. Oncotarget 2016; 7: 7193-7206.